Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Hdl Handle:
http://hdl.handle.net/10675.2/609063
Title:
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Authors:
Cochran, Sam; Hussen, Nebat; Martin, Elise; Raji, Yazdan; Tran, Lynn
Abstract:
Does treatment with sofosbuvir for Hepatitis C genotype 2 or 3 patients for whom peginterferon and ribavirin treatment was not an option lead to a sustained virologic response at 12 week weeks after therapy?
Affiliation:
Medical College of Georgia
Issue Date:
May-2016
URI:
http://hdl.handle.net/10675.2/609063
Type:
Other
Language:
en_US
Description:
Critically appraised topic completed as an assignment in Essentials of Clinical Medicine II
Series/Report no.:
Spring; 2016
Appears in Collections:
Critically Appraised Topics

Full metadata record

DC FieldValue Language
dc.contributor.authorCochran, Samen
dc.contributor.authorHussen, Nebaten
dc.contributor.authorMartin, Eliseen
dc.contributor.authorRaji, Yazdanen
dc.contributor.authorTran, Lynnen
dc.date.accessioned2016-05-11T17:10:26Zen
dc.date.available2016-05-11T17:10:26Zen
dc.date.issued2016-05en
dc.identifier.urihttp://hdl.handle.net/10675.2/609063en
dc.descriptionCritically appraised topic completed as an assignment in Essentials of Clinical Medicine IIen
dc.description.abstractDoes treatment with sofosbuvir for Hepatitis C genotype 2 or 3 patients for whom peginterferon and ribavirin treatment was not an option lead to a sustained virologic response at 12 week weeks after therapy?en
dc.language.isoen_USen
dc.relation.ispartofseriesSpringen
dc.relation.ispartofseries2016en
dc.subjectRandomized Controlled Trialen
dc.subjectHepacivirusen
dc.subjectHepatitis C, Chronicen
dc.subjectDrug Therapy, Combinationen
dc.subjectTreatment Outcomeen
dc.titleSofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsen_US
dc.typeOtheren
dc.contributor.departmentMedical College of Georgiaen
All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.